Profile data is unavailable for this security.
About the company
Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).
- Revenue in USD (TTM)0.00
- Net income in USD-119.19k
- Incorporated2020
- Employees2.00
- LocationEnzolytics Inc120 W Pomona AveMONROVIA 91016United StatesUSA
- Phone+1 (626) 538-4779
- Fax+1 (845) 818-3588
- Websitehttps://enzolytics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alzamend Neuro Inc | 0.00 | -7.39m | 6.57m | 4.00 | -- | -- | -- | -- | -10.69 | -10.69 | 0.00 | -1.41 | 0.00 | -- | -- | 0.00 | -344.10 | -177.86 | -- | -257.81 | -- | -- | -- | -- | -- | -363.62 | -- | -- | -- | -- | 33.14 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 6.70m | 7.00 | -- | 2.12 | -- | 171.28 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -12.19m | 6.72m | 4.00 | -- | 1.05 | -- | -- | -5.26 | -5.30 | 0.00 | 0.9961 | 0.00 | -- | -- | 0.00 | -279.27 | -182.35 | -320.96 | -235.45 | -- | -- | -- | -- | -- | -14.25 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -25.17m | 6.74m | 18.00 | -- | 0.3428 | -- | -- | -11.62 | -11.62 | 0.00 | 6.91 | 0.00 | -- | -- | 0.00 | -69.24 | -46.84 | -83.35 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Eterna Therapeutics Inc | 162.00k | -23.94m | 6.93m | 8.00 | -- | -- | -- | 42.75 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Enzolytics Inc | 0.00 | -119.19k | 6.96m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 6.97m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 7.08m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 7.09m | 75.00 | 0.0003 | 0.00002 | 1.31 | 0.3985 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -137.05m | 7.19m | 16.00 | -- | -- | -- | 31.83 | -5.53 | -5.53 | 0.0102 | 0.241 | 0.0092 | -- | 12.91 | 14,125.00 | -557.63 | -63.43 | -896.39 | -85.72 | -- | -- | -60,641.15 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -1.21m | 7.24m | 3.00 | -- | -- | -- | -- | -0.1674 | -0.1674 | 0.00 | -0.8904 | 0.00 | -- | -- | 0.00 | -634.64 | -- | -- | -- | -- | -- | -- | -- | -- | -14.05 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.18m | -2.21m | 7.26m | 30.00 | -- | 0.7474 | -- | 0.7901 | -0.1108 | -0.1108 | 0.5807 | 0.5403 | 0.9647 | 7.19 | 5.77 | -- | -23.17 | -3.83 | -27.98 | -5.02 | 13.88 | 14.55 | -24.02 | -3.04 | 4.87 | -118.92 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| NuCana PLC (ADR) | 0.00 | -37.54m | 7.29m | 25.00 | -- | 1.44 | -- | -- | -234.80 | -234.80 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -91.91 | -41.01 | -177.64 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0689 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 7.30m | 389.00 | 0.0013 | 0.0001 | 0.7915 | 0.1282 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| Exicure Inc | 500.00k | -8.17m | 7.32m | 5.00 | -- | 4.54 | -- | 14.64 | -4.72 | -4.72 | 0.2889 | 0.9323 | 0.0354 | -- | -- | 83,333.34 | -57.87 | -41.52 | -69.90 | -55.78 | -- | -- | -1,634.40 | -290.95 | -- | -- | 0.3827 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 7.33m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Enzolytics Inc's reporting currency: US Dollar USD
0.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hilltop Partners LLCas of 30 Jun 2024 | 1.95m | 0.06% |
| Vermillion & White Wealth Management Group LLCas of 30 Jun 2024 | 29.86k | 0.00% |
| Strategic Investment Solutions, Inc. (Illinois)as of 30 Jun 2024 | 5.00k | 0.00% |
| HighPoint Advisor Group LLCas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
